The Business of Making a Baby
By Lindsey J. Smith,
San Francisco Magazine [cites CGS' Marcy Darnovsky]
| 03. 23. 2018
After spending her 20s as an aid worker in Africa and India, Helena moved to the Bay Area in 2012, when she was 31. She wanted to apply her public health background to the startup world, so she worked for one health-tech company and then another. She quickly adjusted to life in the city and formed a group of single female friends whose ambitions closely matched her own. To Helena, these young women epitomized the freedom and boundless potential of Silicon Valley: They had worked hard, mapped out paths to promotions, and risen in their fields. They lived as mistresses of their own destinies.
But as their early 30s melted into their mid-30s, a question loomed like storm clouds on the horizon: How and when would any of them have children? Helena (who asked that her last name not be used) and her friends began discussing the option of egg freezing. A consensus soon formed: It was insurance for your future. It let you take your time and find the perfect partner. It would buy you more years to advance...
Related Articles
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...
By Staff, ScienceDaily | 01.05.2026
Scientists at UNSW Sydney have developed a new form of CRISPR technology that could make gene therapy safer while also resolving a decades-long debate about how genes are switched off. The research shows that small chemical markers attached to DNA
...
Following a long-standing CGS tradition, we present a selection of our favorite Biopolitical Times posts of the past year.
In 2025, we published up to four posts every month, written by 12 authors (staff, consultants and allies), some in collaboration and one simply credited to CGS.
These titles are presented in chronological order, except for three In Memoriam notices, which follow. Many more posts that are worth your time can be found in the archive. Scroll down and “VIEW...
By Jonathan Matthews, GMWatch | 12.11.2025
In our first article in this series, we investigated the dark PR tactics that have accompanied Colossal Bioscience’s de-extinction disinformation campaign, in which transgenic cloned grey wolves have been showcased to the world as resurrected dire wolves – a...